Studies โ€บ Follow-up ยท Last reviewed 2026-05-16

Follow-up studies overview

Summary

Long-term data on the Dutch Protocol remain limited. This page collects published cohort and outcome studies, with sample size, follow-up duration, attrition and main findings. The NICE reviews (2020) rated all results as very low certainty (source). The University of York systematic review for the Cass Review (2024) concluded that no conclusions can be drawn about the effect of puberty blockers on gender dysphoria and mental health (source), and the Swedish SBU (2022) found the evidence on hormone treatment insufficient to assess its effects (source).

Overview (selection)

StudynFollow-upMain finding
de Vries 201170Until start of hormones (T1)Behavioural and emotional problems and depressive symptoms decreased and general functioning improved; gender dysphoria and body satisfaction did not change (source)
de Vries 201455โ‰ฅ 1 yr post-opGender dysphoria alleviated; well-being similar to or better than same-age young adults from the general population (source)
Costa et al. 2015201 (UK, GIDS)Measured every 6 monthsGlobal functioning (CGAS) improved after 6 months of psychological support; after 12 months of GnRHa it was higher than when only support was given (source)
Carmichael 202144 (UK, GIDS early intervention)12, 24 and 36 months (44, 24 and 14 participants)No changes in psychological function (source)
Brik et al. 2020143median 0.8 yrs on GnRHa87% started hormones; 6% (9 adolescents) discontinued GnRHa (source)
van der Loos 2022720until end of 201898% (704) were still using hormones at the end of data collection (source)
van der Loos 20231,766retrospective cohort, 20 years1.4% stopped GnRHa, mostly because gender dysphoria remitted (source)

Common limitations

  • No RCTs in this clinical domain.
  • Heterogeneous outcome measures โ€” comparison between studies hindered.
  • Long-term data (10+ years) largely missing.

Conclusion of systematic reviews

SBU (2022) found the evidence on hormone treatment of children with gender dysphoria insufficient to assess its effects (source). The University of York review for the Cass Review (2024) found that of 50 studies on puberty suppression 1 was of high, 25 of moderate and 24 of low quality, and concluded that no conclusions can be drawn about the effect on gender dysphoria and mental health (source).1

Critical note

Most adolescents on puberty blockers went on to hormones: 98% (43 of 44) in the UK early intervention study and 98% and 93% in two Dutch studies (source). Brik et al. describe the GnRHa phase as an "extended diagnostic phase", but also write that the vast majority proceeded to hormones, possibly because the eligibility criteria select those likely to proceed, and that because of the observational design it cannot be said whether the treatment itself influenced the outcome (source). The Cass Review writes that there is no evidence that puberty blockers buy time to think (source). A Finnish register study (Ruuska et al., 2026) found that among adolescents who underwent medical gender reassignment, severe psychiatric morbidity rose during follow-up (from 9.8% to 60.7% for feminising and from 21.6% to 54.5% for masculinising treatment); the authors also report that, after adjusting for prior psychiatric treatment, all gender-referred adolescents had similarly elevated risks (source).2

See also

Footnotes

  1. Taylor J, Mitchell A, Hall R, et al. Interventions to suppress puberty in adolescents experiencing gender dysphoria. Arch Dis Child. 2024; University of York / Cass Review systematic review.
  2. Brik T, Vrouenraets LJJJ, de Vries MC, Hannema SE. Trajectories of adolescents treated with gonadotropin-releasing hormone analogues for gender dysphoria. Arch Sex Behav. 2020;49:2611โ€“2618.